Get the Stockscreener App
1.5406
1.87%
-0.0294
Evogene Ltd stock is traded at $1.5406, with a volume of 73,383.
It is down -1.87% in the last 24 hours and up +17.60% over the past month.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.
See More
Previous Close:
$1.57
Open:
$1.53
24h Volume:
73,383
Relative Volume:
0.04
Market Cap:
$15.08M
Revenue:
$5.64M
Net Income/Loss:
$-23.88M
P/E Ratio:
-2.9068
EPS:
-0.53
Net Cash Flow:
$-22.36M
1W Performance:
-14.88%
1M Performance:
+17.60%
6M Performance:
+24.24%
1Y Performance:
-76.57%
1-Day Range:
$1.52
$1.60
1-Week Range:
$1.34
$1.63
52-Week Range:
$0.95
$7.19
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
1.55 | 15.08M | 5.64M | -23.88M | -22.36M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
517.30 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.03 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
546.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
256.01 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-21 | Initiated | ROTH Capital | Buy |
| Jul-29-21 | Initiated | Aegis Capital | Buy |
| Dec-01-20 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-16-13 | Initiated | Oppenheimer | Outperform |
Evogene Ltd Stock (EVGN) Latest News
Evogene Announces Annual General Meeting for August 2025 - TipRanks
Citadel Advisors LLC Makes New Investment in Evogene Ltd. (NASDAQ:EVGN) - Defense World
Evogene Becomes Talk Of Retail Town As Stock Doubles On GenAI Drug, Agri Discovery Model With Google Cloud - MSN
Cannabis Stocks To Keep An Eye On – June 10th - Defense World
Evogene, Google Cloud innovation to revolutionise ag-chemicals - Far Eastern Agriculture
Evogene Becomes Talk Of Retail Town As Stock Doubles On Genai Drug, Agri Discovery Model With Google Cloud - MENAFN.com
AI And Tech Stocks Climb With Major Partnerships And Innovations - Finimize
Evogene iyo Google Cloud Unveil Model ee Naqshadaynta Molecule Generative, Hormoodka Waa Cusub ee Sayniska Nolosha AI - Unite.AI
AI Innovations Propel Industry Players To New Heights - Finimize
Evogene and Google Cloud Unveil Foundation Model for Generative Molecule Design, Pioneering a New Era in Life-Science AI - Unite.AI
Top Midday Gainers - marketscreener.com
Evogene (EVGN) Stock Nearly Doubles in a Single Day with Explosive 89% Surge - Daily Chhattisgarh News
Evogene’s AI Breakthrough Ignites Stock Surge: What’s Driving the Hype? - RagingBull
Pre-market Movers: EVGN, WINT, CARM, UNCY... - RTTNews
Jane Street Group LLC Acquires Shares of 21,345 Evogene Ltd. (NASDAQ:EVGN) - Defense World
Evogene announces completion of generative AI foundation model with Google Cloud - TipRanks
Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud - PR Newswire
EVGNEvogene Reports First Quarter 2025 Financial Results - mx.advfn.com
Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025 - mx.advfn.com
Evogene price target lowered to $3.50 from $6 at Alliance Global Partners - TipRanks
Evogene Announces Leadership Change and Strategic Shift at Biomica - TipRanks
Evogene (TSE:EVGN) Given a C$1.00 Price Target by Royal Bank of Canada Analysts - Defense World
Evogene's ChemPass AI Tech-Engine is Introduced with New Breakthrough Machine Learning Technology for Target-Protein Discovery - Barchart.com
Evogene Ltd. Earnings Call: Balancing Growth and Challenges - TipRanks
Evogene Ltd (EVGN) Q1 2025 Earnings Call Highlights: Strategic Expense Reductions and Promising ... - Yahoo Finance
Evogene stock target cut to $3.50, maintains buy at Lake Street - Investing.com Nigeria
Evogene price target lowered to $3.50 from $5 at Lake Street - TipRanks
Evogene Ltd. (NASDAQ:EVGN) Q1 2025 Earnings Call Transcript - Insider Monkey
Evogene: Q1 Earnings Snapshot - New Haven Register
Evogene Reports First Quarter 2025 Financial Results - Krishak Jagat
Evogene Ltd. Reports Q1 2025 Financial Results - TipRanks
Evogene earnings beat by $0.35, revenue fell short of estimates - Investing.com Australia
Evogene Q1 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Evogene Reports Narrower Loss in Q1 2025 - Investing.com
Earnings call transcript: Evogene Reports Narrower Loss in Q1 2025 By Investing.com - Investing.com UK
Evogene Announces Q1 2025 Financial Results and Strategic Acquisition - TipRanks
Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com - Defense World
StockNews.com Begins Coverage on Evogene (NASDAQ:EVGN) - Defense World
Evogene (EVGN) Projected to Post Quarterly Earnings on Wednesday - Defense World
Evogene Schedules First Quarter 2025 Financial Results Release - Krishak Jagat
Casterra Announces Additional $2.2 Million of Purchase Orders to Supply Castor Seeds for New African Territories - Barchart.com
Evogene Announces Pricing Of US$8,500,000 Registered Direct Offering - Barchart.com
Evogene (NASDAQ:EVGN) Coverage Initiated by Analysts at StockNews.com - Defense World
Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com - Defense World
Evogene Ltd Stock (EVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):